Related Experiment Video
Updated: Nov 28, 2025
Rapid High-throughput Species Identification of Botanical Material Using Direct Analysis in Real Time High Resolution Mass Spectrometry
Published on: October 2, 2016
Myotoxic Mushroom Poisoning in Thailand: Clinical Characteristics and Outcomes
Satariya Trakulsrichai1,2, Peerawich Jeeratheepatanont1, Charuwan Sriapha2
1Department of Emergency Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok 10400, Thailand.
Purpose:
To describe the clinical characteristics and outcomes of myotoxic mushroom poisoning in Thailand.
Patients And Methods:
We performed a retrospective cohort study of cases of myotoxic mushroom poisoning from the Ramathibodi Poison Center Toxic Exposure Surveillance System during a 5-year period (2012-2016).
Results:
Forty-one cases were included. Most (53.7%) were male with the average age of 49 years. In three cases, the mushrooms were identified as Russula species by an experienced mycologist. Common presenting symptoms were gastrointestinal (GI) symptoms and myalgia. The median onset of GI symptoms and symptoms suggesting rhabdomyolysis after consuming mushrooms was 2 hours (0.17-24 hours) and 24-48 hours (2-120 hours), respectively. Eight patients who ate the mushrooms together with other patients with rhabdomyolysis had GI symptoms but did not develop rhabdomyolysis. For patients with rhabdomyolysis, acute kidney injury (AKI) and hyperkalaemia occurred in 51.5% and 33.3% of cases, respectively. Median initial and maximum creatine phosphokinase (CPK) levels in patients with rhabdomyolysis were 31,145 and 47,861 U/L, respectively. Fifteen of 17 patients who were investigated for troponin levels had elevated troponin. Three patients had a low ejection fraction. Most patients (95.1%) were admitted to hospital, with a median stay of 5 days. The mortality rate was 26.8%. Treatments included intravenous fluid, urine alkalinization, haemodialysis and peritoneal dialysis. Among patients with rhabdomyolysis, AKI, hyperkalaemia during hospitalisation, maximum CPK level, maximum creatinine level and initial and maximum potassium levels were the factors found to be significantly different between patients who died and those who survived.
Conclusion:
Myotoxic mushroom poisoning had a high mortality rate. Most patients had early or delayed onset of clinical symptoms after mushroom ingestion. Some patients developed severe cardiovascular effects. Early detection, close monitoring (especially serum potassium, creatinine, CPK and cardiac effect) and good supportive care were the main treatment modalities.
Insights
Myotoxic mushroom poisoning in Thailand is severe, with a high mortality rate of 26.8%. Early detection and supportive care are crucial for managing symptoms like rhabdomyolysis and acute kidney injury.
Area of Science:
- Toxicology
- Clinical Medicine
- Public Health
Background:
- Mushroom poisoning is a significant public health concern globally.
- Myotoxic mushroom species can cause severe muscle damage and systemic complications.
Purpose of the Study:
- To investigate the clinical features and outcomes of myotoxic mushroom poisoning in Thailand.
- To identify risk factors associated with mortality in these cases.
Main Methods:
- A retrospective cohort study was conducted using data from the Ramathibodi Poison Center Toxic Exposure Surveillance System (2012-2016).
- Forty-one cases of myotoxic mushroom poisoning were analyzed.
Main Results:
- The study identified gastrointestinal symptoms and myalgia as common initial presentations.
- Rhabdomyolysis occurred in a significant proportion of patients, leading to acute kidney injury (51.5%) and hyperkalemia (33.3%).
- The overall mortality rate was 26.8%, with factors like acute kidney injury and hyperkalemia being significantly different between survivors and non-survivors.
Conclusions:
- Myotoxic mushroom poisoning presents with a high mortality rate and varied clinical manifestations, including cardiovascular effects.
- Prompt recognition, intensive monitoring of electrolytes, muscle enzymes, and renal function, alongside supportive care, are essential for patient management.
More Related Videos
07:37Using Terminal Transferase-mediated dUTP Nick End-labelling TUNEL and Caspase 3/7 Assays to Measure Epidermal Cell Death in Frogs with Chytridiomycosis
Published on: May 16, 2018
06:58Author Spotlight: Evaluation of Entomopathogenic Fungi in Wild Monochamus alternatus Populations for Biocontrol Applications in Forest Wood Borers
Published on: September 29, 2023
Related Concept Videos
01:26Anticholinesterase Agents: Poisoning and Treatment
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
01:26Toxic Reactions: Overview
Toxicity falls into two primary categories: local and systemic.
Local toxicity appears at the exposure site, such as protein denaturation caused by caustic substances.
In contrast, systemic toxicity requires the toxic agent's absorption and distribution,...
01:17Antidotes
Specific antidotes operate by inhibiting the enzymes that control biochemical pathways, reducing the production of harmful metabolites.
An example of an antidote is atropine, which counteracts the detrimental effects of cholinesterase inhibitors. It achieves this by deactivating muscarinic receptors,...
01:26Fungal Phylum Basidiomycota
01:14Prevention of Further Absorption of Poison
01:27Myocarditis II: Clinical Features and Diagnostic Tests